DGIdb - MOTESANIB Drug Record

MOTESANIB chembl:CHEMBL572881 Antineoplastic

Alternate Names:

AMG-706
MOTESANIB
AMG 706
N-(2,3-DIHYDRO-3,3-DIMETHYL-1H-INDOL-6-YL)-2-((4-PYRIDINYLMETHYL)AMINO)-3-PYRIDINECARBOXAMIDE
pubchem.compound:11667893
chembl:CHEMBL572881
drugbank:05575
chemidplus:453562-69-1

Drug Info:

FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent
Drug Class	Kinase Inhibitors

(5 More Sources)

Publications:

Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
Coxon et al., 2012, Anti-tumor activity of motesanib in a medullary thyroid cancer model., J. Endocrinol. Invest.
Caenepeel et al., 2010, Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors., J. Exp. Clin. Cancer Res.

MOTESANIB KIT

Interaction Score: 0.76

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Stem cell growth factor receptor inhibitor

Direct Interaction yes

Notes

PMIDs:
20633291

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions
MOTESANIB RET

Interaction Score: 0.75

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type predicted – sensitive

PMIDs:
21422803

Sources:
TALC MyCancerGenome JAX-CKB ChemblInteractions CIViC
MOTESANIB FLT1

Interaction Score: 0.58

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name motesanib diphosphate, AMG 706

Novel drug target Established target

PMIDs:
20124951

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions PharmGKB
MOTESANIB KDR

Interaction Score: 0.49

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

Direct Interaction yes

Trial Name motesanib diphosphate, AMG 706

PMIDs:
20124951 21422803

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions PharmGKB
MOTESANIB PDGFRB

Interaction Score: 0.44

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name motesanib diphosphate, AMG 706

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions
MOTESANIB FLT4

Interaction Score: 0.37

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

Direct Interaction yes

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions
MOTESANIB PDGFRA

Interaction Score: 0.36

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Novel drug target Established target

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions
MOTESANIB YES1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

MyCancerGenome: MOTESANIB
- Version: 20-Jun-2017
Alternate Names:

MOTESANIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
TdgClinicalTrial: MOTESANIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

JAX-CKB: Motesanib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Caenepeel et al., 2010, Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors., J. Exp. Clin. Cancer Res.

Coxon et al., 2012, Anti-tumor activity of motesanib in a medullary thyroid cancer model., J. Endocrinol. Invest.

PharmGKB: motesanib
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
CIViC: MOTESANIB
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Coxon et al., 2012, Anti-tumor activity of motesanib in a medullary thyroid cancer model., J. Endocrinol. Invest.
TALC: MOTESANIB
- Version: 12-May-2016
Alternate Names:

MOTESANIB Primary Drug Name

MOTESANIB Drug Generic Name

Drug Info:

Publications:
DTC: MOTESANIB
- Version: 02-September-2020
Alternate Names:

CHEMBL572881 ChEMBL Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL572881
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL572881
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Stem cell growth factor receptor inhibitor
Direct Interaction	yes
Notes

Evidence Type	Actionable
Approval Status	Preclinical - Cell line xenograft
Response Type	predicted – sensitive

Notes
Trial Name	motesanib diphosphate, AMG 706
Novel drug target	Established target

Mechanism of Interaction	Vascular endothelial growth factor receptor inhibitor
Direct Interaction	yes
Trial Name	motesanib diphosphate, AMG 706

Mechanism of Interaction	Platelet-derived growth factor receptor inhibitor
Direct Interaction	yes
Novel drug target	Established target

MOTESANIB Drug Record

MOTESANIB chembl:CHEMBL572881 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Stem cell growth factor receptor inhibitor Direct Interaction yes Notes

PMIDs: 20633291

Sources: TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell line xenograft Response Type predicted – sensitive

PMIDs: 21422803

Sources: TALC MyCancerGenome JAX-CKB ChemblInteractions CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name motesanib diphosphate, AMG 706 Novel drug target Established target

PMIDs: 20124951

Sources: TALC MyCancerGenome TdgClinicalTrial ChemblInteractions PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor Direct Interaction yes Trial Name motesanib diphosphate, AMG 706

PMIDs: 20124951 21422803

Sources: TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Novel drug target Established target Trial Name motesanib diphosphate, AMG 706

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor Direct Interaction yes Notes

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Direct Interaction yes Novel drug target Established target

PMIDs: None found

Sources: MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

MyCancerGenome: MOTESANIB

Alternate Names: MOTESANIB Generic Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

TdgClinicalTrial: MOTESANIB

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Publications:

JAX-CKB: Motesanib

Alternate Names:

Drug Info:

Publications: Caenepeel et al., 2010, Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors., J. Exp. Clin. Cancer Res. Coxon et al., 2012, Anti-tumor activity of motesanib in a medullary thyroid cancer model., J. Endocrinol. Invest.

PharmGKB: motesanib

Alternate Names:

Drug Info:

Publications: Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics

CIViC: MOTESANIB

Alternate Names:

Drug Info:

Publications: Coxon et al., 2012, Anti-tumor activity of motesanib in a medullary thyroid cancer model., J. Endocrinol. Invest.

TALC: MOTESANIB

Alternate Names: MOTESANIB Primary Drug Name MOTESANIB Drug Generic Name

Drug Info:

Publications:

DTC: MOTESANIB

Alternate Names: CHEMBL572881 ChEMBL Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL572881

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL572881

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Stem cell growth factor receptor inhibitor

Direct Interaction yes

Notes

PMIDs:
20633291

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type predicted – sensitive

PMIDs:
21422803

Sources:
TALC MyCancerGenome JAX-CKB ChemblInteractions CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name motesanib diphosphate, AMG 706

Novel drug target Established target

PMIDs:
20124951

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

Direct Interaction yes

Trial Name motesanib diphosphate, AMG 706

PMIDs:
20124951 21422803

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name motesanib diphosphate, AMG 706

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

Direct Interaction yes

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Novel drug target Established target

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

MOTESANIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

Caenepeel et al., 2010, Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors., J. Exp. Clin. Cancer Res.

Coxon et al., 2012, Anti-tumor activity of motesanib in a medullary thyroid cancer model., J. Endocrinol. Invest.

Publications:

Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics

Publications:

Coxon et al., 2012, Anti-tumor activity of motesanib in a medullary thyroid cancer model., J. Endocrinol. Invest.

Alternate Names:

MOTESANIB Primary Drug Name

MOTESANIB Drug Generic Name

Alternate Names:

CHEMBL572881 ChEMBL Drug ID